Hemochromatosis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hemochromatosis - Pipeline Review, H1 2016', provides an overview of the Hemochromatosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemochromatosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hemochromatosis - The report reviews pipeline therapeutics for Hemochromatosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hemochromatosis therapeutics and enlists all their major and minor projects - The report assesses Hemochromatosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hemochromatosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hemochromatosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hemochromatosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hemochromatosis Overview 6 Therapeutics Development 7 Pipeline Products for Hemochromatosis - Overview 7 Pipeline Products for Hemochromatosis - Comparative Analysis 8 Hemochromatosis - Therapeutics under Development by Companies 9 Hemochromatosis - Therapeutics under Investigation by Universities/Institutes 10 Hemochromatosis - Pipeline Products Glance 11 Hemochromatosis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Hemochromatosis - Products under Development by Companies 13 Hemochromatosis - Products under Investigation by Universities/Institutes 14 Hemochromatosis - Companies Involved in Therapeutics Development 15 Acino International AG 15 Ionis Pharmaceuticals, Inc. 16 La Jolla Pharmaceutical Company 17 Protagonist Therapeutics Inc. 18 Hemochromatosis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Drug for Thalassemia and Hemochromatosis - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 IONIS-TMPRSS6LRx - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 LJPC-401 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 M-012 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 NSC-8679 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 PTG-300 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Recombinant Protein for Iron Overload Disorders - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Hemochromatosis - Recent Pipeline Updates 36 Hemochromatosis - Dormant Projects 38 Hemochromatosis - Product Development Milestones 39 Featured News & Press Releases 39 Feb 24, 2016: Merganser Biotech Initiates First Clinical Trial 39 Oct 19, 2015: La Jolla Pharmaceutical Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload 39 Aug 11, 2015: La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-401 40 Nov 01, 2011: UCLA scientists design experimental treatment for iron-overload diseases 40 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for Hemochromatosis, H1 2016 7 Number of Products under Development for Hemochromatosis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Hemochromatosis - Pipeline by Acino International AG, H1 2016 15 Hemochromatosis - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 16 Hemochromatosis - Pipeline by La Jolla Pharmaceutical Company, H1 2016 17 Hemochromatosis - Pipeline by Protagonist Therapeutics Inc., H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Hemochromatosis Therapeutics - Recent Pipeline Updates, H1 2016 36 Hemochromatosis - Dormant Projects, H1 2016 38
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.